报价延迟最少15分钟:2025/07/21 07:05 EDT
盘前时段
|
||||
|
1.27 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.27
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.87/-0.95
|
|
企业价值
64.54M
|
| 资产负债 |
|
每股账面净值
2.45
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.16M
|
|
每股收益
0.20
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 07:05 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncologyproduct candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595. |
